1 2 2	Compare SGLT2I versus non-SGLT2I users in type-2 diabetic mellitus patients on GLP-1 receptor agonist: A population-based and machine learning causal inference analysis
4	Zhiyao Luo MSc ^{1*} , Oscar Hou-In Chou MSc ^{*2} , Zita Man Wai Ng ³ , Cheuk To Skylar Chung ³ ,
5	Jeffrev Shi Kai Chan MBChB ³ . Raymond Ngai Chiu Chan MBChB ³ . Lei Lu Ph.D. ¹ . Tingting Zhu
6	Ph.D. ¹ , Bernard Man Yung Cheung MB BChir FRCP ² , Tong Liu MD ⁴ , Gary Tse MD DM Ph.D.
7	FRCP FFPH ^{4,5,6,} [^] , Jiandong Zhou Ph.D. ^{7, ^}
8	
9	¹ Institute of Biomedical Engineering, Department of Engineering Science, University of
10	Oxford, Oxford, United Kingdom
11	² Division of Clinical Pharmacology and Therapeutics, Department of Medicine, Li Ka Shing
12	Faculty of Medicine, The University of Hong Kong, Hong Kong, China
13	³ Diabetes Research Unit, Cardiovascular Analytics Group, PowerHealth Limited, Hong Kong,
14	China
15	⁴ Tianiin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease. Department
16	of Cardiology. Tianiin Institute of Cardiology. Second Hospital of Tianiin Medical University.
17	Tianjin 300211, China
18	⁵ Kent and Medway Medical School, Canterbury, Kent, CT2 7NT, United Kingdom
19	⁶ School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong,
20	China
21	⁷ Division of Health Science, Warwick Medical School, University of Warwick, Coventry,
22	United Kingdom
23	
24	
25	* Contributed equally
26	^ Correspondence to:
27	Gary Tse, MD DM PhD FRCP
28	Kent and Medway Medical School, Canterbury, United Kingdom
29	Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin
30	300211, China
31	School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China
32	Email: <u>garytse86@gmail.com</u>
33	liendens Zhav, DhD
34 25	Januong Linu, MiD, Division of Hoalth Science, Warwick Medical School, University of Warwick, United Kingdom
32 32	Empil: iipndong zhou@warwick ac.uk
30 27	
38	
50	

39 Abstract

Background: Both sodium-glucose cotransporter-2 (SGLT2) inhibitors and GLP-1 receptor
agonists (GLP1a) demonstrated benefits against cardiovascular diseases in type 2 diabetes
(T2D). However, the effects of SGLT2I amongst patients already on GLP1a users remain
unknown.

44 **Objective:** This real-world study compared the risks of cardiovascular diseases with and
45 without exposure to SGLT2I amongst GLP1a users.

46 **Methods:** This was a retrospective population-based cohort study of patients with type-2 47 diabetes mellitus (T2DM) on GLP1a between 1st January 2015 and 31st December 2020 using 48 a territory-wide registry from Hong Kong. The primary outcomes were new-onset myocardial 49 infarction, atrial fibrillation, heart failure, and stroke/transient ischaemic attack (TIA). The 50 secondary outcome was all-cause mortality. Propensity score matching (1:2 ratio) using the 51 nearest neighbour search was performed. Multivariable Cox regression was used to identify 52 significant associations. The machine learning causal inference analysis was used to estimate the treatment effect. 53

Results: This cohort included 2526 T2DM patients on GLP1a (median age: 52.5 years old [SD: 54 55 10.9]; 57.34 % males). The SGLT2I users and non-SGLT2I users consisted of 1968 patients and 56 558 patients, respectively. After matching, non-SGLT2I users were associated with high risks 57 of myocardial infarction (Hazard ratio [HR]: 2.91; 95% Confidence Interval [CI]: 1.30-6.59) and heart failure (HR: 2.49; 95% CI: 1.22-5.08) compared to non-SGLT2I users after adjusting for 58 59 demographics, comorbidities, medications, renal function, and glycaemic tests. However, 60 non-SGLT2I users were not associated with the risks of atrial fibrillation (HR: 1.52; 95% CI: 61 0.65-3.53) and stroke/TIA (HR: 1.72; 95% CI: 0.70-4.24). The results remained consistent in 62 the competing risk and the sensitivity analyses.

- 63 Conclusions: SGLT2I non-users was associated with higher risks of myocardial infarction and
- 64 heart failure when compared to SGLT2I users after adjustments amongst T2DM patients on
- 65 GLP1a. The result remained consistent in the machine learning causal inference analysis.
- 66
- 67 Keywords
- 68 Sodium-glucose cotransporter-2 inhibitors; glucagon-like peptide-1 receptor agonist;
- 69 cardiovascular disease; Myocardial infarction; Stroke; Atrial fibrillation
- 70

71 Graphical abstract

Compare SGLT2I versus non-SGLT2I users in type-2 diabetic mellitus patients on GLP-1 receptor agonist: A population-based and machine learning causal inference analysis



73 Introduction

Cardiovascular diseases are one of the leading causes of mortality and morbidity 74 75 worldwide amongst patients with type 2 diabetes mellitus (T2DM) [1]. To reduce the risks of 76 cardiovascular diseases, current clinical guidelines highlight the importance of a multifactorial 77 approach in diabetic management, including the use of anti-diabetic agents [2, 3]. The current 78 literature suggests that novel anti-diabetic medications such as sodium-glucose 79 cotransporter-2 inhibitors (SGLT2I) and glucagon-like peptide receptor agonists (GLP1a) 80 demonstrate promising protective effects against various major adverse cardiovascular 81 events (MACE) and mortality [4-6].

82 Some studies suggested that the cardiovascular benefit of SGLT2I and GLP1a is 83 enhanced when used in conjunction [7]. A real-world cohort study demonstrates that the 84 addition of SGLT2I amongst GLP1a diabetic users showed superior cardioprotective effects 85 compared to the addition of sulfonylurea [8]. It was proposed that the molecular mechanism 86 of the cardioprotective effects of SGLT2i and GLP1a could complement each other. However, 87 the real-world evidence surrounding whether adding SGLT2I would benefit cardiovascular outcomes amongst patients using GLP1a remains limited. Previously, it was suggested that 88 89 amongst patients on SGLT2I, only 4.4% of the patients had baseline GLP1a uses [9]. The recent 90 development of machine learning (ML) for causal inference may also be applied to better 91 characterize the treatment effects of anti-diabetic agents [10]. Therefore, this present study aims to examine the effect of SGLT2I and GLP1a on cardiovascular outcomes with ML causal 92 93 inference in a T2DM cohort from Hong Kong.

94

95 Methods

96 This study was approved by the Institutional Review Board of the University of Hong
97 Kong/Hospital Authority Hong Kong West Cluster Institutional Review Board (HKU/HA HKWC
98 IRB) (UW-20-250 and UW 23-339) and complied with the Declaration of Helsinki.

99

100 Study population

101 This was a retrospective population-based study of prospectively collected electronic 102 health records using the Clinical Data Analysis and Reporting System (CDARS) by the Hospital 103 Authority (HA) of Hong Kong. The records cover both public hospitals and their associated 104 outpatient clinics as well as ambulatory and day-care facilities in Hong Kong. This system has 105 been used extensively by our teams and other research teams in Hong Kong, including 106 diabetes and medication research.[11, 12] The system contains data on disease diagnosis, 107 laboratory results, past comorbidities, clinical characteristics, and medication prescriptions. 108 T2DM patients who were administered with GLP1a in centres under the HA, between 1st January 2015, to 31st December 2020, were included. 109

110

111 Predictors and variables

Patients' demographics include gender and age of initial drug use (baseline), clinical 112 113 and biochemical data were extracted for the present study. Prior comorbidities were 114 extracted by the International Classification of Diseases Ninth Edition (ICD-9) codes (Supplementary Table 1). The diabetes duration was calculated by examining the earliest 115 116 date amongst the first date of (1) diagnosis using ICD-9; (2) HbA1c \geq 6.5%; (3) Fasting glucose 117 ≥7.0 mmol/l or Random glucose 11.1 mmol/l; (4) using anti-diabetic medications. The patients 118 on financial aid were defined as patients on the Comprehensive Social Security Assistance 119 (CSSA) scheme, higher disability allowance, normal disability allowance, waiver, and other

financial aid in Hong Kong. The number of hospitalisations in the year prior to the index days 120 121 was extracted. The Charlson standard comorbidity index was calculated. [13] The baseline 122 laboratory examinations, including the glucose profiles and renal function tests, were 123 extracted. The estimated glomerular filtration rate (eGFR) was calculated using the 124 abbreviated modification of diet in renal disease (MDRD) formula. [14] Furthermore, the 125 time-weighted lipid and glucose profiles after drug initiation were also calculated by the 126 products of the sums of two consecutive measurements and the time interval, then divided 127 by the total time interval, as suggested previously.[15]

128

129 Study outcomes

130 The primary outcome of this study was new-onset PAD defined using ICD-9 code 131 enlisted in **Supplementary Table 1**. Mortality data were obtained from the Hong Kong Death 132 Registry, a population-based official government registry with the registered death records of 133 all Hong Kong citizens linked to CDARS. Mortality was recorded using the International 134 Classification of Diseases Tenth Edition (ICD-10) coding. The as-treat approach was adopted 135 which patients were censored at treatment discontinuation or switching of the comparison 136 medications. The endpoint date of interest for eligible patients was the event presentation 137 date. The endpoint for those without primary outcomes was the mortality date or the end of 138 the study period (31st December 2020).

139

140 Statistical analysis

141 Descriptive statistics are used to summarize baseline clinical and biochemical 142 characteristics of patients with and without SGLT2I use. For baseline clinical characteristics,

143 continuous variables were presented as mean (95% confidence interval/standard deviation), 144 and the categorical variables were presented as total numbers (percentage). Propensity score 145 matching generated by logistic regression with a 1:2 ratio for SGLT2I users versus non-users 146 based on demographics, prior anti-diabetic drugs, number of prior anti-diabetic drugs, prior 147 comorbidities, renal function, duration from T2DM diagnosis initial drug exposure, HbA1c and 148 fasting glucose were performed using the nearest neighbour search strategy with a calliper of 149 0.1 (Figure 1). Propensity score matching was performed using Stata software (Version 16.0). 150 Baseline characteristics between patients with and without SGLT2I use before and after 151 matching were compared with absolute standardized mean difference (SMD), with SMD<0.20 152 regarded as well-balanced between the two groups.

153 The cumulative incidence curves for the primary outcomes and secondary outcomes 154 were constructed. Cox proportional hazards regression was used to identify significant risk 155 predictors of adverse study outcomes in the matched cohort, with adjustments for 156 demographics, comorbidities, number of prior hospitalisations, medication profile, renal 157 function, glycaemic tests, and the duration of T2DM. The log-log plot was used to verify the 158 proportionality assumption for the proportional Cox regression models. Subgroup analyses 159 were conducted to confirm the association amongst patients with different clinically 160 important predictors accounting to the diabetic and the metabolic profile, as well as the 161 comorbidities and medications associated with the outcome.

162 Cause-specific and sub-distribution hazard models were conducted to consider possible 163 competing risks. Multiple propensity adjustment approaches were used, including propensity 164 score stratification,[16] propensity score with inverse probability of treatment weighting 165 (IPTW) [17] and propensity score with stable inverse probability weighting.[18]. In the 166 sensitivity analysis, patients with less than 3-month follow-up duration, patients with chronic

kidney disease (CKD) stage 4/5 (eGFR <30 mL/min/1.73m^2), patients on financial aid, and patients at the top or bottom 5% of propensity score matching were excluded to test the robustness of the association. We used the hip fracture as the negative control in the falsification analysis, such that the observed significant association in the falsification analysis should be attributed to bias. The hazard ratio (HR), 95% Cl, and P-value were reported. Statistical significance was defined as P-value <0.05. All statistical analyses were performed with RStudio (Version: 1.1.456) and Python (Version: 3.6).

174

175 Causal Random Forest Model

In clinical research, discerning causal links between treatments and outcomes is
essential. While prediction models offer insights into probable outcomes based on various
factors, they do not capture intervention causal effects[19], which is crucial distinction when
assessing intervention efficacy [20].

180 Causal Random Forests (CRFs) stand at the confluence of machine learning and causal 181 inference, leveraging the robust capabilities of random forests to specifically estimate 182 heterogeneous treatment effects [21]. CRFs adeptly uncover intricate, non-linear dynamics 183 between treatments and outcomes. CRFs manage high-order interactions, pinpointing 184 patient subgroups deriving maximum or minimum benefit from a treatment.

185 Let Y(t) be the potential outcome at time t under treatment A, where A can be 0 186 (no SGLTI-2) or 1 (SGLTI-2). Our objective is to estimate the Conditional Average Treatment 187 Effect (CATE) for time t:

188
$$CATE(t) = E[Y(t) | A = 1] - E[Y(t) | A = 0]$$

For a given patient *i*, let W_i represent its covariates, A_i its treatment status, and $Y_i(t)$ the observed outcome at time *t*. In CRFs, each tree *b* in the forest aims to predict the potential outcome differences $Y_i(t)$ for treatment versus control. The splitting criterion in CRFs is based on maximizing the difference in treatment effects between the two child nodes. Specifically, the impurity decrease in a node split is calculated as:

194
$$\Delta I = \frac{n_{left}}{n} Var_{left}(Y(t)|A=1) - Var_{left}(Y(t)|A=0) + \frac{n_{right}}{n} Var_{right}(Y(t)|A=1) - Var_{right}(Y(t)|A=0)$$

195

where *n* is the total number of observations in the current node, n_{left} and n_{right} are the number of observations in the left and right child nodes, and Var_{left} and Var_{right} are the variances of the potential outcomes in the left and right child nodes, respectively.

199 In essence, the CRF optimization process is driven by finding splits that result in nodes 200 with high differences in treatment effects, which, in turn, reveals subgroups with varying 201 responses to treatment. Once the forest is constructed, the CATE for a new observation x at 202 time t is estimated as:

203

$$\widehat{CATE}(t,x) = \frac{1}{B} \sum_{b=1}^{B} \frac{1}{n_{b,1}} \left(\sum_{i:A_i=1}^{A} Y_i(t) - \frac{1}{n_{b,0}} \sum_{i:A_i=0}^{A} Y_i(t) \right)$$

where *B* is the number of trees in the forest, $n_{b,1}$ and $n_{b,0}$ are the number of treated and control observations, respectively, in tree *b* for which *x* falls in the terminal node.

206

207 Results

208

In this territory-wide cohort study of 2526 patients (median age: 52.5 years old [SD: 10.9]; 57.34 % males) with T2DM treated with GLP1a between 1st January 2015 and 31st December 2020 in Hong Kong, patients were followed up until 31st December 2020 or until

their deaths (Figure 1). This study included 1068 patients (77.91%) who used SGLT2Is, and
558 patients (22.09%) who did not use SGLT2I (Table 1). Before matching, fewer SGLT2 users
had hypertension and were on less medications (metformin, anticoagulants, ACEI/ARB,
diuretics).

216 After the propensity score matching, the baseline characteristics and the timeweighted lipid and glucose profiles of the two groups were well-balanced (Table 1). The 217 218 SGLT2I and non-SGLT2I users were comparable after matching with the nearest neighbour 219 search strategy with a calliper of 0.1, and there was no violation of the proportional hazard 220 assumption (Supplementary Figure 1). In the matched cohort, 43 patients developed 221 myocardial infarction (2.56%), 26 patients developed atrial fibrillation (1,55%), 59 patients 222 developed heart failure (3.52%), and 30 patients developed stroke/TIA (1.79%). The 223 characteristics of patients by drug use before and after propensity score matching are shown 224 in Table 1.

225

226 Association between SGLT2I and non-SGLT2I users and cardiovascular outcomes

227 In the matched cohort, 21 SGLT2I users and 22 non-SGLT2I users developed 228 myocardial infarction. After a total follow-up of 9176.7 person-year, the incidence of 229 myocardial infarction was lower amongst SGLT2I users (Incidence rate [IR] per 1000 person-230 vear: 3.4; 95% CI: 2.1-5.2) compared to non-SGLT2I users (IR per 1000 person-year: 7.3; 95% 231 CI: 4.6-11.0) (Table 2). Non-SGLT2I users had a higher risk of myocardial infarction after 232 adjustment (HR: 2.91; 95% CI: 1.30-6.50, p=0.0092) compared to SGLT2I users regardless of 233 the demographics, comorbidities, medication profile, renal function, glycaemic tests, number 234 of hospitalisations, and the duration of T2DM (Table 2). This was substantiated by the

cumulative incidence curves (Figure 2). The E-value for the myocardial infarction was 5.27,
which suggested that the unobserved confounding variable with at least a 5.26-fold stronger
association with myocardial infarction would be needed to explain the significant HR, but
weaker confounding could not do so (Supplementary Figure 4).

Besides, 13 SGLT2I users and 13 non-SGLT2I users developed atrial fibrillation. After a total follow-up of 9220.2 person-year, the incidence of atrial fibrillation was lower amongst SGLT2I users (IR per 1000 person-year: 2.1; 95% CI: 1.1-3.6) compared to non-SGLT2I users (IR per 1000 person-year: 4.3; 95% CI: 2.3-7.3) (Table 2). Non-SGLT2I users did not had a significant risk of atrial fibrillation after adjustment (HR: 1.52; 95% CI: 0.65-3.53, p=0.3335) compared to SGLT2I users after adjustments (Table 2). This was substantiated by the cumulative incidence curves (Figure 2).

Furthermore, 31 SGLT2I users and 28 non-SGLT2I users developed heart failure. After a total follow-up of 9146.1 person-year, the incidence of heart failure was lower amongst SGLT2I users (IR per 1000 person-year: 5.1; 95% CI: 3.4-7.2) compared to non-SGLT2I users (IR per 1000 person-year: 9.3; 95% CI: 6.2-13.4) (Table 2). Non-SGLT2I users had a significant high risk of heart failure after adjustment (HR: 2.49; 95% CI: 1.22-5.08, p=0.0121) compared to SGLT2I users after adjustments (Table 2). This was substantiated by the cumulative incidence curves (Figure 2). The E-value for the heart failure was 4.42.

Finally, 14 SGLT2I users and 16 non-SGLT2I users developed stroke/TIA. After a total follow-up of 9213.8 person-year, the incidence of stroke/TIA was lower amongst SGLT2I users (IR per 1000 person-year: 2.3; 95% CI: 1.2-3.8) compared to non-SGLT2I users (IR per 1000 person-year: 5.2; 95% CI: 3.05-8.5) **(Table 2)**. Compared to SGLT2I users, non-SGLT2I users did not have significantly different risk of stroke/TIA after adjustment (HR: 1.72; 95% CI: 0.70-

4.24, p=0.2361) (Table 2). This was substantiated by the cumulative incidence curves (Figure
259 2).

260

261 Association between SGLT2I and non-users and all-cause mortality

Overall, 15 SGLT2I users and 13 non-SGLT2I users passed away. After a follow-up of 9313.1 person-year, the incidence of all-cause mortality was lower amongst SGLT2I users (IR: 2.4; 95% CI: 1.4-4.0) compared to non-users (IR: 4.2; 95% CI: 2.2-7.2) (Table 2). Non-SGLT2I users were not associated with higher risks of all-cause mortality after adjustment (HR: 1.66; 95% CI: 0.61-4.52, p=0.3184) compared to non-SGLT2I users after adjustments (Table 2). This was substantiated by the cumulative incidence curves (Figure 2).

268

269 Subgroup analysis

270 The results of the subgroup analysis for effects of SGLT2I and non-SGLT2I users on the 271 cardiovascular outcomes are shown in Figure 3. The result demonstrated that non-SGLT21 users was associated with higher risks of myocardial infarction amongst patients without prior 272 273 ischaemic heart disease. Besides, non-SGLT2I users were associated with higher risks of atrial 274 fibrillation amongst female, with hypertension, hyperlipidaemia, on insulin, and on dipeptidyl 275 peptidase-4 inhibitor (DPP4I). Furthermore, non-SGLT2I users were associated with higher 276 risks of heart failure amongst female, with hypertension, hyperlipidaemia, without prior ischaemic heart disease, and on DPP4I. Lastly, non-SGLT2I users were associated with higher 277 278 risks of stroke/TIA amongst patients with hypertension, on insulin, and without DPP4I.

The marginal effects analysis demonstrated that SGLT2I use was associated with lower risks of cardiovascular disease regardless of the time-weighted mean fasting glucose level apart from atrial fibrillation. Meanwhile, the differences between SGLT2I users and non-SLGT2I users on myocardial infarction, atrial fibrillation, and stroke/TIA became smaller as the time-weighted mean of HbA1c level increases (**Supplementary Figure 2**).

284

285 Sensitivity analysis

286 Sensitivity analyses were performed to confirm the predictability of the models and test the potential effects on bias. The results of the cause-specific hazard models, sub-287 288 distribution hazard models and different propensity score approaches demonstrated that 289 different models did not change the point estimates for both the myocardial infarction (all 290 p<0.05) (Supplementary Table 2). However, non-SGLT2I users were associated with a higher 291 risk of stroke/TIA compared to SGLT2I users. The association between SGLT2I users and non-292 SGLT2I users on myocardial infarction and heart failure remained consistent after 1) excluding patients with less than 3-month follow-up duration; 2) Exclude patients with CKD stage 4/5 293 294 (eGFR <30), peritoneal dialysis or haemodialysis; 3) Excluding patients on financial aid; 4) 295 Exclude patients at the top or bottom 5% of propensity score matching (Supplementary Table 296 3).

297

298 Machine learning causal inference analysis results

The causal inference analysis was performed using Casual Survival Forests model. The result demonstrated that SGLT2I demonstrated a higher estimated treatment effects (ETE) against myocardial infarction (Averaged treatment effect [ATE]: 0.009; 95% CI: 0.005-0.012;

p=0.0012) and heart failure (ATE: 0.017; 95% CI: 0.012-0.023; p=0007), atrial fibrillation (ATE:
0.013; 95% CI: 0.009-0.018; p=0.0041), and stroke/TIA (ATE: 0.029; 95% CI: 0.022-0.032;
p<0.0001) (Figure 4). Here ATE is calculated by ETE of SGLT2I minus ETE of non-SGLT2I.
Furthermore, for the significant outcome myocardial infarction and heart failure in Table 2,
in the causal inference analysis, SGLT2I users demonstrated a greater estimated treatment
effects compared to non-SGLT2I users regardless of sex, hyperlipidaemia, hypertension, prior
ischaemic heart disease and insulin (Supplementary Figure 3).

309

310 Falsification analysis

Hip fracture was used as negative control outcome in the falsification analysis for the comparison between SGLT2I and non-SGLT2I users **(Supplementary Table 4)**. The results demonstrated that non-SGLT2I users' risk of the hip fracture after adjustment (HR: 0.91; 95% CI: 0.82-1.79, p=0.2311) were not significantly different from SGLT2I users.

315

316 Discussion

In this territory-wide cohort study, real-world data was used to compare the association between SGLT2I usage and cardiovascular events amongst patients on GLP1a. The results suggest that non-SGLT2I users demonstrated a significantly higher risk of myocardial infarction and heart failure than SGLT2I users. Meanwhile, in the machine learning causal inference analysis, the result demonstrated that amongst patients on GLP1a, SGLT2I had a larger estimated treatment effect compared to non-SGLT2I users on cardiovascular outcomes.

324 Comparison with previous studies

A recent consensus report jointly issued by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) has presented an extensive guideline endorsing the utilization of SGLT2I, as well as GLP-1A for individuals with T2DM with increased risk of cardiovascular disease and heart failure [22]. However, limited emphasis is placed on delineating the potential cardioprotective benefits arising from a combined therapy involving SGLT2I and GLP-1A.

331 In our study, we observed a notable increase in the risks of myocardial infarction and 332 heart failure amongst SGLT2I non-users compared to the SGLT2I users in patients on GLP1a. 333 The result remained consistent with a meta-analysis, which demonstrated that SGLT2I was 334 associated with lower risks of heart failure compared to non-SGLT2I users, which was 335 consistent with the clinical trial data [23]. Furthermore, in the meta-analysis including 97 trials, 336 SGLT2I was associated with a lower risk of myocardial infarction compared to control with an 337 HR of 0.86 [24]. SGLT2I has also demonstrated its protective effect against new-onset 338 myocardial infarction compared to DPP4I in a Hong Kong population-based study (HR: 0.81) 339 [25]. Yet, upon conversion, the equivalent HR for myocardial infarction amongst GLP1a patients in this study was 0.48, much lower than the published figures. This might indirectly 340 341 imply that SGLT2I might exert greater protective effects amongst GLP1a patients. 342 Nevertheless, evidence suggests SGLT2I was not significantly associated with a lower risk of 343 acute coronary artery syndrome compared to non-SGLT2I users amongst elderly T2DM patients [26] and patients with renal failure [27]. These differences could be explained by the 344 345 baseline atherosclerotic profile and the cardiorenal status; in this study, GLP1a alone, with or 346 without interacting with SGLT2I, might have already improved those factors [28, 29].

347 While our findings corroborate the existing literature concerning the association 348 between SGLT2I and a reduction in MACE, the underlying mechanistic pathways remain an

imperative area for ongoing investigation. It was previously suggested that a combination of both SGLT2I and GLP1a could demonstrate superior glycaemic control with a greater reduction in the HbA1c compared to using either alone [30]. The associations between the use of SGLT2I and atrial fibrillation or stroke/TIA were not statistically significant. However, this could be explained by the relatively low case numbers for those outcomes.

The promise of the SGLT2I/GLP1a combination therapy in T2DM patients is evident in a post-hoc analysis derived from the EXSCEL trial; the result demonstrated that the combination of SGLT2I and GLP-1A yielded a decreased risk of MACE (HR: 0.68) compared to GLP-1A alone (HR: 0.85) [31]. Meanwhile, a US-based real-world cohort study showcased an overall risk reduction effect resulting from the addition of SGLT2I to the GLP1A regimen on MACE, but not for stroke [8]. This raised the possibility that SGLT2I might play a slightly lesser role in preventing stroke [32, 33].

361 The ML causal inference analysis was designed to distinguish between causal 362 relationships and spurious correlations and would provide actionable information regarding the treatment [34]. The estimated treatment difference was defined as the difference in the 363 predicted outcome for patients treated with that drug versus their outcome if they had not 364 365 been treated [34]. This approach has been used to compare the effects of antidiabetic drugs 366 amongst poorly controlled diabetes patients [35]. In our ML causal inference analysis, the 367 result demonstrated that SGLT2I demonstrated higher estimated treatment effects against all 4 outcomes we investigated in this study. Besides, the causal ML method demonstrated 368 369 that differences in outcomes with and without the usage of SGLT2I remained consistent 370 across different subgroups, such that the effects of SGLT2I remained homogenous.

371

372 Clinical implications

373 As the prevalence of T2DM continues to rise in Asia [36], the expanding body of 374 literature concerning the potential cardioprotective benefits of antidiabetic drugs holds 375 significant relevance. Under the current reference framework in Hong Kong designates 376 metformin as the first-line therapy for T2DM [37, 38], with second-line antidiabetic drugs to 377 be added when the glucose levels are insufficiently controlled. In our study, the number 378 needed to treat for myocardial infarction and heart failure was 49 and 45, respectively 379 (Supplementary Table 5). While affirming the favourable cardioprotective effects of SGLT21 380 supplementation for GLP1a-treated T2DM patients, this study also underscores the necessity 381 for further trials and in-depth investigations to ascertain whether these outcomes are solely attributable to SGLT2I or result from synergistic effect with GLP1a. 382

383

384 Limitations

However, there are some limitations to the study. The observational nature of this study suggests that data on certain variables, namely alcohol use, BMI, smoking, family history and physical activity, could not be obtained and analysed. In compensation for this, laboratory results and comorbidities related to the cardiovascular outcomes were used to infer possible risk factors. To corroborate, drug cohorts were matched over a variety of medications and diseases, adjusted with regression, and performed sensitivity analyses to reduce the effect of the confounders.

The observational design of this study inherently lacks randomization, introducing potential biases. While propensity score matching was employed to mitigate confounding, the possibility of unidentified residual confounding remains. Therefore, a falsification analysis was conducted, and the result did not falsify the association observed. Additionally, the observational nature of the study precludes the establishment of definitive causal

397	relationships. Yet, the incorporation of the machine learning approaches arguably holds
398	promise in unravelling causal relationships, further accentuating the associations between
399	SGLT2I usage and cardiovascular outcomes.
400	
401	Conclusion
402	This population-based cohort study suggested that non-SGLT2I users were associated
403	with higher risks of myocardial infarction and heart failure compared to SGLT2I users amongst
404	T2DM patients currently on GLP1a. These findings were substantiated by the machine
405	learning causal inference analysis.
406 407	
408	Funding source
409	The authors received no funding for the research, authorship, and/or publication of this
410	article.
411	
412	Ethical approval statement
413	This study was approved by the Institutional Review Board of the University of Hong
414	Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKWC IRB) (UW-20-250), and New
415	Territories East Cluster-Chinese University of Hong Kong (NTEC-UCHK) Clinical Research
416	Ethnics Committee (2018.309, 2018.643) and complied with the Declaration of Helsinki.
417	
418	Conflicts of Interest
419	None.
420	

421 Availability of data and materials

Data are not available, as the data custodians (the Hospital Authority and the Department of Health of Hong Kong SAR) have not given permission for sharing due to patient confidentiality and privacy concerns. Local academic institutions, government departments, or nongovernmental organizations may apply for the access to data through the Hospital Authority's data sharing portal (https://www3.ha.org.hk/data).

427

428 Acknowledgements

429 None.

430

431 Guarantor Statement

- 432 All authors approved the final version of the manuscript. GT is the guarantor of this work and,
- 433 as such, had full access to all the data in the study and takes responsibility for the integrity of
- 434 the data and the accuracy of the data analysis.

435

436 Author contributions

- 437 Data analysis: ZYL, OHIC, JZ
- 438 Data review: ZYL, OHIC, CTC, GT, JZ
- 439 Data acquisition: OHIC, ZMWN, GT
- 440 Data interpretation: OHIC, CTC, JSKC, GT, JZ
- 441 Critical revision of manuscription: ZYL, RNCC, TTZ, TL, LL, JSKC, GT, JZ
- 442 Supervision: TTZ, TL, BMYC, GT, JZ

- 443 Manuscript writing: ZYL, OHIC, CTC, JSKC, JZ
- 444 Manuscript revision: ZYL, OHIC, CTC, JSKC, JZ

References

- Raghavan S, Vassy JL, Ho YL, Song RJ, Gagnon DR, Cho K, Wilson PW, Phillips LS: Diabetes mellitus–related all-cause and cardiovascular mortality in a national cohort of adults. *Journal of the American Heart Association* 2019, 8(4):e011295.
- 2. Association AD: American Diabetes Association Standards of medical care in diabetes–2017. *Diabetes care* 2017, 40(Suppl. 1):S1.
- Group ESD: 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal 2020, 41(2):255-323.
- Kyriakos G, Quiles-Sanchez LV, Garmpi A, Farmaki P, Kyre K, Savvanis S, Antoniou VK, Memi E: SGLT2 Inhibitors and Cardiovascular Outcomes: Do they Differ or there is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study. Curr Cardiol Rev 2020, 16(4):258-265.
- Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, Ceriello A, Chiodini P, Esposito K: GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovascular Diabetology 2021, 20(1):189.
- Lin TK, Lee MC, Cheng YH, Ma T, Chen MC, Yang TY, Jong GP: The association between SGLT2 inhibitors and new-onset acute coronary syndrome in the elderly: a population-based longitudinal cohort study. *Diabetol Metab Syndr* 2023, 15(1):170.
- Neves JS, Borges-Canha M, Vasques-Nóvoa F, Green JB, Leiter LA, Granger CB, Carvalho D, Leite-Moreira A, Hernandez AF, Del Prato S: GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with Type 2 diabetes. *Journal* of the American College of Cardiology 2023, 82(6):517-525.
- Dave CV, Kim SC, Goldfine AB, Glynn RJ, Tong A, Patorno E: Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy. *Circulation* 2021, 143(8):770-779.
- Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017, 377(7):644-657.
- 10. Venkatasubramaniam A, Mateen BA, Shields BM, Hattersley AT, Jones AG, Vollmer SJ, Dennis JM: Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine. *BMC Med Inform Decis Mak* 2023, **23**(1):110.
- 11. Zhou J, Zhang G, Chang C, Chou OHI, Lee S, Leung KSK, Wong WT, Liu T, Wai AKC, Cheng SH *et al*: **Metformin versus sulphonylureas for new onset atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based study**. *Acta Diabetol* 2022, **59**(5):697-709.
- 12. Chou OHI, Zhou J, V Mui J, Satti DI, Chung CT, Tai Loy Lee T, Lee S, Dee EC, Ng K, Cheung BMY *et al*: Lower risks of new-onset acute pancreatitis and pancreatic cancer in sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors: A propensity score-matched study with competing risk analysis. *Diabetes Epidemiology and Management* 2023, 9:100115.
- 13. Charlson ME, Carrozzino D, Guidi J, Patierno C: **Charlson Comorbidity Index: A Critical Review of Clinimetric Properties**. *Psychother Psychosom* 2022, **91**(1):8-35.

- 14. Soliman AR, Fathy A, Khashab S, Shaheen N: Comparison of abbreviated modification of diet in renal disease formula (aMDRD) and the Cockroft-Gault adjusted for body surface (aCG) equations in stable renal transplant patients and living kidney donors. Ren Fail 2013, 35(1):94-97.
- 15. Wu M-Z, Chandramouli C, Wong P-F, Chan Y-H, Li H-L, Yu S-Y, Tse Y-K, Ren Q-W, Yu S-Y, Tse H-F et al: Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors. Diabetes & Metabolism 2022, 48(6):101367.
- 16. Austin PC: An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res 2011, 46(3):399-424.
- 17. Austin PC, Stuart EA: Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015, 34(28):3661-3679.
- 18. Avagyan V, Vansteelandt S: Stable inverse probability weighting estimation for longitudinal studies. Scandinavian Journal of Statistics 2021, 48(3):1046-1067.
- 19. van Geloven N, Swanson SA, Ramspek CL, Luijken K, van Diepen M, Morris TP, Groenwold RHH, van Houwelingen HC, Putter H, le Cessie S: Prediction meets causal inference: the role of treatment in clinical prediction models. Eur J Epidemiol 2020, **35**(7):619-630.
- 20. Muriel A, Hernández-Marrero D, Abraira V: Longitudinal observational studies and causality. Nefrología (English Edition) 2012, 32(1):12-14.
- 21. Wager S, Athey S: Estimation and Inference of Heterogeneous Treatment Effects using Random Forests. Journal of the American Statistical Association 2018, **113**(523):1228-1242.
- 22. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G et al: Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022, **65**(12):1925-1966.
- 23. Ryan PB, Buse JB, Schuemie MJ, DeFalco F, Yuan Z, Stang PE, Berlin JA, Rosenthal N: Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab 2018, 20(11):2585-2597.
- 24. Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K: Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagonlike Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Metaanalysis. Jama 2018, 319(15):1580-1591.
- 25. Zhou J, Lee S, Leung KSK, Wai AKC, Liu T, Liu Y, Chang D, Wong WT, Wong ICK, Cheung BMY et al: Incident heart failure and myocardial infarction in sodiumglucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users. ESC Heart Failure 2022, **9**(2):1388-1399.
- 26. Lin T-K, Lee M-C, Cheng Y-H, Ma T, Chen M-C, Yang T-Y, Jong G-P: The association between SGLT2 inhibitors and new-onset acute coronary syndrome in the elderly: a population-based longitudinal cohort study. Diabetology & Metabolic Syndrome 2023, 15(1):170.

- 27. Birkeland KI, Bodegard J, Banerjee A, Kim DJ, Norhammar A, Eriksson JW, Thuresson M, Okami S, Ha KH, Kossack N et al: Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab 2021, 23(1):75-85.
- 28. Caruso I, Cignarelli A, Sorice GP, Natalicchio A, Perrini S, Laviola L, Giorgino F: Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies. Metabolites 2022, 12(2).
- 29. Marx N, Husain M, Lehrke M, Verma S, Sattar N: GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. *Circulation* 2022, **146**(24):1882-1894.
- 30. Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA: Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2016, 4(12):1004-1016.
- 31. Clegg LE, Penland RC, Bachina S, Boulton DW, Thuresson M, Heerspink HJL, Gustavson S, Sjöström CD, Ruggles JA, Hernandez AF et al: Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovasc Diabetol 2019, 18(1):138.
- 32. Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, Lam CSP, Lopes RD, McMurray JJV, Pratley RE et al: Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021, 9(10):653-662.
- 33. Strain WD, Frenkel O, James MA, Leiter LA, Rasmussen S, Rothwell PM, Sejersten Ripa M, Truelsen TC, Husain M: Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6. Stroke 2022, 53(9):2749-2757.
- 34. Crown WH: Real-World Evidence, Causal Inference, and Machine Learning. Value Health 2019, 22(5):587-592.
- Belthangady C, Giampanis S, Jankovic I, Stedden W, Alves P, Chong S, Knott C, 35. Norgeot B: Causal deep learning reveals the comparative effectiveness of antihyperglycemic treatments in poorly controlled diabetes. Nature *Communications* 2022, **13**(1):6921.
- Yuan H, Li X, Wan G, Sun L, Zhu X, Che F, Yang Z: Type 2 diabetes epidemic in East 36. Asia: a 35-year systematic trend analysis. Oncotarget 2018, 9(6):6718-6727.
- 37. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020, 43(Suppl 1):S98-s110.
- Hong Kong Reference Framework for Diabetes Care for Adults in Primary Care 38. Settings. In: Reference Frameworks. Health Bureau; 2021.



Figure 1. Procedures of data processing for the study cohort

SGLT2I: Sodium-glucose cotransporter-2 inhibitors; MDRD: modification of diet in renal disease.





Figure 2. Cumulative incidence curves for new onset cardiovascular outcomes and all-cause mortality stratified by drug exposure effects of SGLT2I users and non-SGLT2I users after propensity score matching (1:2).

SGLT2I: Sodium-glucose cotransporter-2 inhibitors;





medRxiv preprint doi: https://doi.org/10.1101/2023.11.06.23298185; this version posted November 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC 4.0 International license .





SGLT2I: Sodium-glucose cotransporter-2 inhibitors; DPP4I: Dipeptidyl peptidase-4 inhibitors; TIA: Transient ischaemic attack





Figure 4. Treatment effect estimated by machine learning causal inference analysis. SGLT2I: Sodium-glucose cotransporter-2 inhibitors

Table 1. Baseline and clinical characteristics of patients with SGLT2I users versus SGLT2I non-users amongst GLP1A users before and after propensity score matching (1:2).

* for SMD≥0.1; SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor; MDRD: modification of diet in renal disease; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin II receptor blockers.

	Before matching				After matching			
Characteristi cs	All (N=2526) Mean(SD);N or Count(%)	Non-SGLT2I users (N=558) Mean(SD);N or Count(%)	SGLT2I users (N=1968) Mean(SD);N or Count(%)	SM D	All (N=1674) Mean(SD);N or Count(%)	Non-SGLT2I users (N=558) Mean(SD);N or Count(%)	SGLT2I users (N=1116) Mean(SD);N or Count(%)	SM D
Demographi								
<i>cs</i> Male gender	1479(58.55%)	320(57.34%)	1159(58.89%)	0.0 3	978(58.42%)	320(57.34%)	658(58.96%)	0.0 3
Female gender	1047(41.44%)	238(42.65%)	809(41.10%)	0.0 3	696(41.57%)	238(42.65%)	458(41.03%)	0.0 3
Baseline age, years	52.5(10.9);n= 2526	53.1(11.4);n =558	52.3(10.7);n= 1968	0.0 7	52.5(10.7);n= 1674	53.1(11.4);n =558	52.2(10.4);n= 1116	0.0 9
Past comorbiditie s								
Charlson standard comorbidity index	1.1(1.1);n=25 26	1.2(1.1);n=5 58	1.1(1.1);n=19 68	0.0 5	1.1(1.0);n=16 74	1.2(1.1);n=5 58	1.1(1.0);n=11 16	0.1
Financial aid	42(1.66%)	6(1.07%)	36(1.82%)	0.0 6	18(1.07%)	6(1.07%)	12(1.07%)	<0. 01
Duration from earliest diabetes mellitus diagnosis date to baseline date, day	8.1(4.7);n=25 26	8.07(4.84);n =558	8.05(4.65);n= 1968	<0. 01	8.2(4.7);n=16 74	8.1(4.8);n=5 58	8.2(4.7);n=11 16	0.0
Number of hospitalizatio ns	1.3(0.9);n=25 26	1.27(0.81);n =558	1.3(0.96);n=1 968	0.0 4	1.2(0.8);n=16 74	1.3(0.8);n=5 58	1.2(0.7);n=11 16	0.0 7
Diabetic retinopathy	248(9.81%)	48(8.60%)	200(10.16%)	0.0 5	125(7.46%)	48(8.60%)	77(6.89%)	0.0 6
Diabetic nephropathy	28(1.10%)	9(1.61%)	19(0.96%)	0.0 6	25(1.49%)	9(1.61%)	16(1.43%)	0.0 1
Diabetic neuropathy	77(3.04%)	19(3.40%)	58(2.94%)	0.0 3	51(3.04%)	19(3.40%)	32(2.86%)	0.0 3
Hyperlipidae mia	1636(64.76%)	341(61.11%)	1295(65.80%)	0.1	1027(61.35%)	341(61.11%)	686(61.46%)	0.0 1
Hypertensio n	1351(53.48%)	360(64.51%)	991(50.35%)	0.2 9*	1004(59.97%)	360(64.51%)	644(57.70%)	0.1 4

		It is made avail		-110 4.	.0 International licen	5e.		
lschemic heart disease	236(9.34%)	51(9.13%)	185(9.40%)	0.0 1	130(7.76%)	51(9.13%)	79(7.07%)	0.0 8
Liver diseases	52(2.05%)	14(2.50%)	38(1.93%)	0.0 4	37(2.21%)	14(2.50%)	23(2.06%)	0.0 3
Renal diseases	221(8.74%)	42(7.52%)	179(9.09%)	0.0 6	108(6.45%)	42(7.52%)	66(5.91%)	0.0 6
Prior acute myocardial infarction	59(2.33%)	13(2.32%)	46(2.33%)	<0. 01	34(2.03%)	13(2.32%)	21(1.88%)	0.0 3
Prior heart failure	69(2.73%)	17(3.04%)	52(2.64%)	0.0 2	48(2.86%)	17(3.04%)	31(2.77%)	0.0 2
Prior stroke/transi ent ischemic attack	45(1.78%)	7(1.25%)	38(1.93%)	0.0 5	21(1.25%)	7(1.25%)	14(1.25%)	<0. 01
Prior atrial fibrillation	30(1.18%)	7(1.25%)	23(1.16%)	0.0 1	21(1.25%)	7(1.25%)	14(1.25%)	<0. 01
Cancer	37(1.46%)	7(1.25%)	30(1.52%)	0.0 2	21(1.25%)	7(1.25%)	14(1.25%)	<0. 01
Medications								
Number of anti-diabetic drug classes	4.4(0.6);n=25 26	4.41(0.59);n =558	4.41(0.63);n= 1968	0.0 1	4.4(0.6);n=16 74	4.41(0.59);n =558	4.44(0.58);n= 1116	0.0 5
Metformin	2298(90.97%)	543(97.31%)	1755(89.17%)	0.3 3*	1623(96.95%)	543(97.31%)	1080(96.77%)	0.0 3
Sulphonylure a	1495(59.18%)	354(63.44%)	1141(57.97%)	0.1 1	1069(63.85%)	354(63.44%)	715(64.06%)	0.0 1
Insulin	2040(80.76%)	448(80.28%)	1592(80.89%)	0.0 2	1345(80.34%)	448(80.28%)	897(80.37%)	<0. 01
Acarbose	153(6.05%)	30(5.37%)	123(6.25%)	0.0 4	76(4.54%)	30(5.37%)	46(4.12%)	0.0 6
Thiozolidine done	1193(47.22%)	240(43.01%)	953(48.42%)	0.1 1	746(44.56%)	240(43.01%)	506(45.34%)	0.0 5
DPP4I	850(33.65%)	190(34.05%)	660(33.53%)	0.0 1	489(29.21%)	190(34.05%)	299(26.79%)	0.1 6
Anticoagulan ts	1166(46.15%)	318(56.98%)	848(43.08%)	0.2 8*	868(51.85%)	318(56.98%)	550(49.28%)	0.1 5
Antiplatelets	511(20.22%)	129(23.11%)	382(19.41%)	0.0 9	346(20.66%)	129(23.11%)	217(19.44%)	0.0 9
Lipid- Iowering drugs	1173(46.43%)	290(51.97%)	883(44.86%)	0.1 4	814(48.62%)	290(51.97%)	524(46.95%)	0.1
Statins and fibrates	1694(67.06%)	370(66.30%)	1324(67.27%)	0.0 2	1135(67.80%)	370(66.30%)	765(68.54%)	0.0 5
Nitrates	271(10.72%)	57(10.21%)	214(10.87%)	0.0 2	157(9.37%)	57(10.21%)	100(8.96%)	0.0 4
ACEI/ARB	1163(46.04%)	303(54.30%)	860(43.69%)	0.2 1*	834(49.82%)	303(54.30%)	531(47.58%)	0.1 3

medRxiv preprint doi: https://doi.org/10.1101/2023.11.06.23298185; this version posted November 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.								
		It is made avail	able under a CC-BY	-NC 4.	0 International licen	ISE .		0.0
hypertension	981(38.83%)	157(28.13%)	824(41.86%)	0.2 9*	501(29.92%)	157(28.13%)	344(30.82%)	0.0 6
Diuretics for heart failure	264(10.45%)	52(9.31%)	212(10.77%)	0.0 5	138(8.24%)	52(9.31%)	86(7.70%)	0.0 6
Beta- blockers	639(25.29%)	110(19.71%)	529(26.88%)	0.1 7	343(20.48%)	110(19.71%)	233(20.87%)	0.0 3
Calcium channel blockers (dihydropyri dine)	874(34.60%)	185(33.15%)	689(35.01%)	0.0 4	541(32.31%)	185(33.15%)	356(31.89%)	0.0 3
Calcium channel blocker (non- dihydropyridi ne)	17(0.67%)	3(0.53%)	14(0.71%)	0.0 2	9(0.53%)	3(0.53%)	6(0.53%)	<0. 01
<i>Calculated biomarkers</i> Abbreviated MDRD, mL/min/1.73 m^2 <i>Lipid and</i> <i>glucose</i>	91.7(26.5);n= 2232	87.9(28.0);n =465	92.7(26.0);n= 1767	0.1 8	93.3(27.3);n= 1364	90.7(30.5);n =465	94.6(25.3);n= 899	0.1 4
profiles Time weighted mean of triglyceride, mmol/L	2.1(0.9);n=24 51	2.09(0.99);n =542	2.06(0.94);n= 1909	0.0 3	2.0(0.9);n=16 03	2.1(1.0);n=5 42	2.0(0.9);n=10 61	0.1 1
weighted mean of low- density lipoprotein, mmol/L	2.2(0.4);n=24 42	2.15(0.43);n =540	2.15(0.42);n= 1902	0.0 1	2.1(0.4);n=16 00	2.2(0.4);n=5 40	2.1(0.4);n=10 60	0.0 5
Time weighted mean of high-density lipoprotein, mmol/L	1.1(0.2);n=24 51	1.14(0.17);n =542	1.15(0.16);n= 1909	0.0 1	1.1(0.2);n=16 03	1.14(0.17);n =542	1.14(0.15);n= 1061	0.0 1
Time weighted mean of total cholesterol, mmol/L	4.3(0.5);n=24 51	4.28(0.46);n =542	4.26(0.48);n= 1909	0.0 3	4.2(0.4);n=16 03	4.3(0.5);n=5 42	4.2(0.4);n=10 61	0.1 3
Time weighted	7.6(1.4);n=21 52	7.4(1.5);n=4 48	7.6(1.4);n=17 04	0.1 3	7.5(1.3);n=13 37	7.4(1.5);n=4 48	7.6(1.3);n=88 9	0.1

		it is made avail	lable under a CC-D	1-INC 4	.0 International licer	ise.		
mean of HbA1C, %								
Time weighted		()						
mean of	8.5(2.2);n=22	8.7(2.4);n=4	8.5(2.1);n=18	⁵ 0 1	8.6(2.0);n=14	8.7(2.4);n=4	8.5(1.8);n=99	0.0
fasting	90	86	04	0.1	84	86	8	8
glucose, mmol/L								

Table 2. Incidence rate (IR) per 1000 person-year and multivariate Cox regression models of new onset cardiovascular disease and all-cause mortality in the cohort amongst GLP1A users before and after 1:2 propensity score matching.

* for $p \le 0.05$, ** for $p \le 0.01$, *** for $p \le 0.001$; CI: confidence interval; SGLT2I: sodium glucose cotransporter-2 inhibitor

Adjusted for significant demographics, past comorbidities, duration of diabetes mellitus, and number of prior hospitalizations, number of anti-diabetic drug classes, other anti-diabetic medications, abbreviated MDRD, HbA1c, fasting glucose.

Myocardial infarction	Number of	Number of	Total person-	Incidence [95%	Adjusted hazard ratio	P-value
	patients	events	year	CI]	[95% CI]	
				per 1000		
				person-time		
SGLT2I users	1116	21	6153.1	3.4[2.1-5.2]	1 [Reference]	NA
Non-SGLT2I users	558	22	3023.6	7.3[4.6-11.0]	2.91[1.30-6.50]	0.0092**
Atrial fibrillation	Number of	Number of	Total person-	Incidence [95%	Adjusted hazard ratio	P value
	patients	events	year	CI]	[95% CI]	
				per 1000		
				person-time		
SGLT2I users	1116	13	6162.8	2.1[1.1-3.6]	1 [Reference]	NA
Non-SGLT2I users	558	13	3057.4	4.3[2.3-7.3]	1.52[0.65-3.53]	0.3335
Heart failure	Number of	Number of	Total person-	Incidence [95%	Adjusted hazard ratio	P-value
	patients	events	year	CI]	[95% CI]	
				per 1000		
				person-time		
SGLT2I users	1116	31	6131.3	5.1[3.4-7.2]	1 [Reference]	NA
Non-SGLT2I users	558	28	3014.8	9.3[6.2-13.4]	2.49[1.22-5.08]	0.0121*
Stroke/ transient	Number of	Number of	Total person-	Incidence [95%	Adjusted hazard ratio	P-value
ischemic attack	patients	events	year	CI]	[95% CI]	
				per 1000		
				person-time		
SGLT2I users	1116	14	6165.8	2.3[1.2-3.8]	1 [Reference]	NA
Non-SGLT2I users	558	16	3048	5.2[3.05-8.5]	1.72[0.70-4.24]	0.2361
All-cause mortality	Number of	Number of	Total person-	Incidence [95%	Adjusted hazard ratio	P value
	patients	events	year	CI]	[95% CI]	
				per 1000		
				person-time		
SGLT2I users	1116	15	6215.3	2.4[1.4-4.0]	1 [Reference]	NA
Non-SGLT2I users	558	13	3097.8	4.2[2.2-7.2]	1.66[0.61-4.52]	0.3184